<p>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 獲取免費報告) 的股價在週四交易前出現下跌，原因是其財報低於預期。該股票此前收於 232.55 美元，但開盤價為 205.00 美元。Ligand Pharmaceuticals 的股票最後交易價格為 211.97 美元，成交量為 88,559 股。</p>
<p>獲取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
<p>這家生物技術公司報告本季度每股收益為 1.63 美元，低於分析師一致預期的 1.84 美元，差距為 0.21 美元。該公司本季度的收入為 5172 萬美元，而分析師預期為 5910 萬美元。Ligand Pharmaceuticals 的股本回報率為 13.86%，淨利潤率為 46.42%。該公司的季度收入同比增長 14.1%。去年同期，該公司每股收益為 1.33 美元。</p>
<h2>分析師評級變動</h2>
<p>多位分析師最近對該股票發表了評論。HC Wainwright 在 2020 年 4 月 30 日的研究報告中將 Ligand Pharmaceuticals 的目標價從 243.00 美元上調至 289.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 2020 年 5 月 1 日的研究報告中將 Ligand Pharmaceuticals 的評級從 “持有 (c)” 上調至 “持有 (c+)”。花旗在 2020 年 4 月 15 日的研究報告中將 Ligand Pharmaceuticals 的目標價從 276.00 美元上調至 282.00 美元，並給予該股票 “買入” 評級。Oppenheimer 在 2020 年 2 月 27 日的研究報告中將 Ligand Pharmaceuticals 的目標價從 275.00 美元上調至 277.00 美元，並給予該股票 “跑贏大盤” 評級。最後，美國銀行在 2020 年 3 月 11 日的研究報告中開始覆蓋 Ligand Pharmaceuticals 的股票，設定 “買入” 評級和 244.00 美元的目標價。七位分析師給予該股票 “買入” 評級，一位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 256.29 美元。</p>
<p><strong>查看我們最新的 LGND 股票報告</strong></p>
<h2>內部交易活動</h2>
<p>在相關消息中，董事 John W. Kozarich 在 2020 年 4 月 1 日以平均價格 202.23 美元出售了 467 股 Ligand Pharmaceuticals 的股票，總價值為 94,441.41 美元。出售後，該董事持有公司 42,253 股股票，價值約為 8,544,824.19 美元。此交易代表其持股比例下降了 1.09%。該交易已在證券交易委員會的法律文件中披露，可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 Andrew Reardon 在 2020 年 3 月 4 日以平均價格 206.35 美元出售了 5,000 股 Ligand Pharmaceuticals 的股票，總交易額為 1,031,750.00 美元。出售完成後，該內部人士直接持有公司 36,869 股股票，價值為 7,607,918.15 美元。這代表其持股比例下降了 11.94%。該銷售的 SEC 文件提供了更多信息。內部人士在上個季度出售了 35,448 股公司股票，價值為 7,450,977 美元。公司內部人士持有公司 7.00% 的股份。</p>
<h2>機構投資者對 Ligand Pharmaceuticals 的看法</h2>
<p>多家機構投資者最近增加或減少了對 LGND 的持股。Envestnet Asset Management Inc.在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 16.6%。Envestnet Asset Management Inc.目前持有 31,915 股該生物技術公司的股票，價值 5,653,000 美元，此前在上個季度購買了 4,538 股。Fisher Asset Management LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 2.7%。Fisher Asset Management LLC 目前持有 108,926 股該生物技術公司的股票，價值 19,295,000 美元，此前在上個季度購買了 2,860 股。馬薩諸塞金融服務公司在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 59.5%。馬薩諸塞金融服務公司目前持有 541,845 股該生物技術公司的股票，價值 95,982,000 美元，此前在上個季度購買了 202,103 股。Lisanti Capital Growth LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 178.0%。Lisanti Capital Growth LLC 目前持有 29,677 股該生物技術公司的股票，價值 5,257,000 美元，此前在上個季度購買了 19,002 股。最後，Cibc World Market Inc.在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 11.7%。Cibc World Market Inc.目前持有 59,131 股該生物技術公司的股票，價值 10,474,000 美元，此前在上個季度購買了 6,209 股。機構投資者和對沖基金持有公司 91.28% 的股份。</p>
<h2>Ligand Pharmaceuticals 股票表現</h2>
<p>該公司的債務與股本比率為 0.44，速動比率為 21.98，流動比率為 22.23。該公司的 50 日簡單移動平均為 211.74 美元，200 日簡單移動平均為 200.35 美元。該公司的市值為 42.9 億美元，市盈率為 36.94，PEG 比率為 1.68，貝塔值為 1.20。</p>
<h2>關於 Ligand Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Ligand Pharmaceuticals, Inc 是一家生物製藥公司，收購、開發和外許可專有技術，旨在幫助製藥和生物技術公司發現和開發新藥。Ligand 主要通過其研究服務和產生特許權使用費的業務運營，專注於建立多樣化的技術平台組合，並與行業領導者合作，推動多個疾病領域的治療候選藥物的進展。</p>
<p>該公司的產品提供圍繞幾個核心平台。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，而非 Ligand Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 在 Ligand Pharmaceuticals 嗎？</h2>
<p>在考慮 Ligand Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Ligand Pharmaceuticals 並不在名單上。</p>
<p>雖然 Ligand Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Ligand制藥

<p>Ligand Pharmaceuticals（納斯達克代碼：LGND）在報告令人失望的財報後，股價跳空下跌至 205.00 美元，盈利每股（EPS）為 1.63 美元，未能達到預期的 1.84 美元。收入為 5172 萬美元，低於預期的 5910 萬美元，儘管同比增長了 14.1%。分析師的評級意見不一，普遍共識為 “適度買入”，平均目標價為 256.29 美元。內部交易活動包括董事的股票出售，機構投資者持有 91.28% 的股份。該股票最後交易價為 211.97 美元，成交量為 88,559 股</p>

<p>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report)'s share price gapped down prior to trading on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $232.55, but opened at $205.00. Ligand Pharmaceuticals shares last traded at $211.97, with a volume of 88,559 shares changing hands.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 獲取免費報告) 的股價在週四交易前出現下跌，原因是其財報低於預期。該股票此前收於 232.55 美元，但開盤價為 205.00 美元。Ligand Pharmaceuticals 的股票最後交易價格為 211.97 美元，成交量為 88,559 股。</p>
</div><p>Get <strong>Ligand Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
</div><p>The biotechnology company reported $1.63 EPS for the quarter, missing analysts' consensus estimates of $1.84 by ($0.21). The company had revenue of $51.72 million during the quarter, compared to analyst estimates of $59.10 million. Ligand Pharmaceuticals had a return on equity of 13.86% and a net margin of 46.42%.The firm's revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter last year, the business earned $1.33 earnings per share.</p>
<div class="lb-trans"><p>這家生物技術公司報告本季度每股收益為 1.63 美元，低於分析師一致預期的 1.84 美元，差距為 0.21 美元。該公司本季度的收入為 5172 萬美元，而分析師預期為 5910 萬美元。Ligand Pharmaceuticals 的股本回報率為 13.86%，淨利潤率為 46.42%。該公司的季度收入同比增長 14.1%。去年同期，該公司每股收益為 1.33 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of analysts recently commented on the stock. HC Wainwright lifted their target price on shares of Ligand Pharmaceuticals from $243.00 to $289.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, April 30th. Weiss Ratings raised shares of Ligand Pharmaceuticals from a &#34;hold (c)&#34; rating to a &#34;hold (c+)&#34; rating in a research report on Friday, May 1st. Citigroup raised their price target on shares of Ligand Pharmaceuticals from $276.00 to $282.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, April 15th. Oppenheimer raised their price target on shares of Ligand Pharmaceuticals from $275.00 to $277.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, February 27th. Finally, Bank of America started coverage on shares of Ligand Pharmaceuticals in a research report on Wednesday, March 11th. They set a &#34;buy&#34; rating and a $244.00 price target for the company. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $256.29.</p>
<div class="lb-trans"><p>多位分析師最近對該股票發表了評論。HC Wainwright 在 2020 年 4 月 30 日的研究報告中將 Ligand Pharmaceuticals 的目標價從 243.00 美元上調至 289.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 2020 年 5 月 1 日的研究報告中將 Ligand Pharmaceuticals 的評級從 “持有 (c)” 上調至 “持有 (c+)”。花旗在 2020 年 4 月 15 日的研究報告中將 Ligand Pharmaceuticals 的目標價從 276.00 美元上調至 282.00 美元，並給予該股票 “買入” 評級。Oppenheimer 在 2020 年 2 月 27 日的研究報告中將 Ligand Pharmaceuticals 的目標價從 275.00 美元上調至 277.00 美元，並給予該股票 “跑贏大盤” 評級。最後，美國銀行在 2020 年 3 月 11 日的研究報告中開始覆蓋 Ligand Pharmaceuticals 的股票，設定 “買入” 評級和 244.00 美元的目標價。七位分析師給予該股票 “買入” 評級，一位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 256.29 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on LGND</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 LGND 股票報告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In related news, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.23, for a total value of $94,441.41. Following the sale, the director owned 42,253 shares of the company's stock, valued at approximately $8,544,824.19. This trade represents a 1.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Reardon sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $206.35, for a total transaction of $1,031,750.00. Following the completion of the sale, the insider directly owned 36,869 shares in the company, valued at $7,607,918.15. This represents a 11.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 35,448 shares of company stock valued at $7,450,977 in the last quarter. Company insiders own 7.00% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 John W. Kozarich 在 2020 年 4 月 1 日以平均價格 202.23 美元出售了 467 股 Ligand Pharmaceuticals 的股票，總價值為 94,441.41 美元。出售後，該董事持有公司 42,253 股股票，價值約為 8,544,824.19 美元。此交易代表其持股比例下降了 1.09%。該交易已在證券交易委員會的法律文件中披露，可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 Andrew Reardon 在 2020 年 3 月 4 日以平均價格 206.35 美元出售了 5,000 股 Ligand Pharmaceuticals 的股票，總交易額為 1,031,750.00 美元。出售完成後，該內部人士直接持有公司 36,869 股股票，價值為 7,607,918.15 美元。這代表其持股比例下降了 11.94%。該銷售的 SEC 文件提供了更多信息。內部人士在上個季度出售了 35,448 股公司股票，價值為 7,450,977 美元。公司內部人士持有公司 7.00% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Ligand Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in LGND. Envestnet Asset Management Inc. boosted its stake in Ligand Pharmaceuticals by 16.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 31,915 shares of the biotechnology company's stock worth $5,653,000 after purchasing an additional 4,538 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Ligand Pharmaceuticals by 2.7% during the 3rd quarter. Fisher Asset Management LLC now owns 108,926 shares of the biotechnology company's stock worth $19,295,000 after purchasing an additional 2,860 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Ligand Pharmaceuticals by 59.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 541,845 shares of the biotechnology company's stock worth $95,982,000 after purchasing an additional 202,103 shares during the last quarter. Lisanti Capital Growth LLC boosted its stake in Ligand Pharmaceuticals by 178.0% during the 3rd quarter. Lisanti Capital Growth LLC now owns 29,677 shares of the biotechnology company's stock worth $5,257,000 after purchasing an additional 19,002 shares during the last quarter. Finally, Cibc World Market Inc. boosted its stake in Ligand Pharmaceuticals by 11.7% during the 3rd quarter. Cibc World Market Inc. now owns 59,131 shares of the biotechnology company's stock worth $10,474,000 after purchasing an additional 6,209 shares during the last quarter. Institutional investors and hedge funds own 91.28% of the company's stock.</p>
<div class="lb-trans"><p>多家機構投資者最近增加或減少了對 LGND 的持股。Envestnet Asset Management Inc.在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 16.6%。Envestnet Asset Management Inc.目前持有 31,915 股該生物技術公司的股票，價值 5,653,000 美元，此前在上個季度購買了 4,538 股。Fisher Asset Management LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 2.7%。Fisher Asset Management LLC 目前持有 108,926 股該生物技術公司的股票，價值 19,295,000 美元，此前在上個季度購買了 2,860 股。馬薩諸塞金融服務公司在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 59.5%。馬薩諸塞金融服務公司目前持有 541,845 股該生物技術公司的股票，價值 95,982,000 美元，此前在上個季度購買了 202,103 股。Lisanti Capital Growth LLC 在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 178.0%。Lisanti Capital Growth LLC 目前持有 29,677 股該生物技術公司的股票，價值 5,257,000 美元，此前在上個季度購買了 19,002 股。最後，Cibc World Market Inc.在第三季度將其在 Ligand Pharmaceuticals 的持股增加了 11.7%。Cibc World Market Inc.目前持有 59,131 股該生物技術公司的股票，價值 10,474,000 美元，此前在上個季度購買了 6,209 股。機構投資者和對沖基金持有公司 91.28% 的股份。</p>
</div><h2>Ligand Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Ligand Pharmaceuticals 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 0.44, a quick ratio of 21.98 and a current ratio of 22.23. The firm's 50 day simple moving average is $211.74 and its 200-day simple moving average is $200.35. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 36.94, a PEG ratio of 1.68 and a beta of 1.20.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.44，速動比率為 21.98，流動比率為 22.23。該公司的 50 日簡單移動平均為 211.74 美元，200 日簡單移動平均為 200.35 美元。該公司的市值為 42.9 億美元，市盈率為 36.94，PEG 比率為 1.68，貝塔值為 1.20。</p>
</div><h2>About Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Ligand Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals, Inc 是一家生物製藥公司，收購、開發和外許可專有技術，旨在幫助製藥和生物技術公司發現和開發新藥。Ligand 主要通過其研究服務和產生特許權使用費的業務運營，專注於建立多樣化的技術平台組合，並與行業領導者合作，推動多個疾病領域的治療候選藥物的進展。</p>
</div><p>The company's product offerings center around several core platforms.</p>
<div class="lb-trans"><p>該公司的產品提供圍繞幾個核心平台。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Ligand Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Ligand Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Ligand Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Ligand Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ligand Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Ligand Pharmaceuticals 並不在名單上。</p>
</div><p>While Ligand Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ligand Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Ligand 製藥（NASDAQ:LGND）在收益未達預期後股價出現跳空下跌